Literature DB >> 27605239

Soluble transferrin receptor levels are positively associated with insulin resistance but not with the metabolic syndrome or its individual components.

Milton Fabian Suárez-Ortegón1, Stela McLachlan1, Sarah H Wild1, José Manuel Fernández-Real2, Caroline Hayward3, Ozren Polašek4.   

Abstract

The metabolic syndrome (MetS) is known to be associated with elevated serum ferritin levels. The possible association with other Fe markers has been less well studied. We aimed to investigate the cross-sectional association of soluble transferrin receptor (sTfR) and ferritin levels with the MetS components, insulin resistance and glycosylated Hb (HbA1C). The sample consisted of 725 adults, aged 19-93 years (284 men, 151 premenopausal and 290 postmenopausal women), from the Croatian island of Vis. Serum sTfR and ferritin levels were measured by immunoturbidimetry and electrochemiluminescence assays, respectively. The MetS was defined using modified international consensus criteria. Logistic and linear regression analyses were conducted to investigate the associations adjusting for age, fibrinogen, smoking status, alcohol consumption and BMI. Prevalence of the MetS was 48·7 %. Standardised values of ferritin were positively associated with all of the MetS components (except high blood pressure and waist circumference) in men (P0·05). sTfR levels could be spuriously elevated in subjects with insulin resistance and without association with the MetS or its components. We conclude that different markers of Fe metabolism are not consistently associated with cardiometabolic risk.

Entities:  

Keywords:  HFG high fasting glucose; HOMA-IR homoeostatic model assessment for insulin resistance; HbA1C glycosylated Hb; MetS metabolic syndrome; WC waist circumference; sTfR soluble transferrin receptor; Ferritin; Insulin resistance; Metabolic syndrome; Soluble transferrin receptor

Mesh:

Substances:

Year:  2016        PMID: 27605239      PMCID: PMC5860738          DOI: 10.1017/S0007114516002968

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  40 in total

Review 1.  Iron metabolism.

Authors:  P Aisen; M Wessling-Resnick; E A Leibold
Journal:  Curr Opin Chem Biol       Date:  1999-04       Impact factor: 8.822

Review 2.  Association of iron indices and type 2 diabetes: a meta-analysis of observational studies.

Authors:  Ester Orban; Sigrid Schwab; Barbara Thorand; Cornelia Huth
Journal:  Diabetes Metab Res Rev       Date:  2014-07       Impact factor: 4.876

Review 3.  Iron deficiency and cardiovascular disease: an updated review of the evidence.

Authors:  Emanuela Lapice; Maria Masulli; Olga Vaccaro
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

4.  Association of serum ferritin with metabolic syndrome and diabetes mellitus in the South Korean general population according to the Korean National Health and Nutrition Examination Survey 2008.

Authors:  Byung-Kook Lee; Yangho Kim; Young-Il Kim
Journal:  Metabolism       Date:  2011-04-12       Impact factor: 8.694

Review 5.  Soluble transferrin receptor for the evaluation of erythropoiesis and iron status.

Authors:  Yves Beguin
Journal:  Clin Chim Acta       Date:  2003-03       Impact factor: 3.786

Review 6.  Transferrin receptor 2: a new molecule in iron metabolism.

Authors:  Debbie Trinder; Erica Baker
Journal:  Int J Biochem Cell Biol       Date:  2003-03       Impact factor: 5.085

Review 7.  Serum transferrin receptor.

Authors:  J D Cook; B S Skikne; R D Baynes
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

8.  Biomarkers of body iron stores and risk of developing type 2 diabetes.

Authors:  S N Rajpathak; J Wylie-Rosett; M J Gunter; A Negassa; G C Kabat; T E Rohan; J Crandall
Journal:  Diabetes Obes Metab       Date:  2009-01-21       Impact factor: 6.577

Review 9.  Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Zhuoxian Zhao; Sheyu Li; Guanjian Liu; Fangfang Yan; Xuelei Ma; Zeyu Huang; Haoming Tian
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

10.  Future of biobanks - bigger, longer, and more dimensional.

Authors:  Ozren Polasek
Journal:  Croat Med J       Date:  2013-10-28       Impact factor: 1.351

View more
  5 in total

1.  Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk.

Authors:  Ricardo José Tofano; Leticia Maria Pescinni-Salzedas; Eduardo Federighi Baisi Chagas; Claudia Rucco Penteado Detregiachi; Elen Landgraf Guiguer; Adriano Cressoni Araujo; Marcelo Dib Bechara; Claudio José Rubira; Sandra Maria Barbalho
Journal:  Diabetes Metab Syndr Obes       Date:  2020-09-24       Impact factor: 3.168

2.  Increased Serum Soluble Transferrin Receptor Levels Were Associated With High Prevalence of Cardiovascular Diseases: Insights From the National Health and Nutrition Examination Survey 2017-2018.

Authors:  Shiyu Zhu; Chang Liu; Chengchen Zhao; Guanzhong Chen; Simin Meng; Ma Hong; Meixiang Xiang; Yao Xie
Journal:  Front Cell Dev Biol       Date:  2022-04-12

3.  Markers of Iron Status Are Associated with Risk of Hyperuricemia among Chinese Adults: Nationwide Population-Based Study.

Authors:  Xiangping Li; Tingchao He; Kai Yu; Qian Lu; Rashad Alkasir; Guifang Guo; Yong Xue
Journal:  Nutrients       Date:  2018-02-09       Impact factor: 5.717

4.  Serum ferritin, an early marker of cardiovascular risk: a study in Chinese men of first-degree relatives with family history of type 2 diabetes.

Authors:  Jun-Ru Liu; Yang Liu; Fu-Zai Yin; Bo-Wei Liu
Journal:  BMC Cardiovasc Disord       Date:  2019-04-03       Impact factor: 2.298

5.  Iron Metabolism Contributes to Prognosis in Coronary Artery Disease: Prognostic Value of the Soluble Transferrin Receptor Within the AtheroGene Study.

Authors:  Henri Weidmann; Johannes H Bannasch; Christoph Waldeyer; Apurva Shrivastava; Sebastian Appelbaum; Francisco Miguel Ojeda-Echevarria; Renate Schnabel; Karl J Lackner; Stefan Blankenberg; Tanja Zeller; Mahir Karakas
Journal:  J Am Heart Assoc       Date:  2020-04-23       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.